05
Mar

Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $4 billion a year.

…read more

Source: Novartis’ ‘breakthrough’ muscle drug is worth $4B, if you ask MorphoSys

    

0 No comments